Your browser doesn't support javascript.
loading
Effect of buffer on the immune response to trivalent oral poliovirus vaccine in Bangladesh: a community based randomized controlled trial.
Chandir, Subhash; Ahamed, Kabir U; Baqui, Abdullah H; Sutter, Roland W; Okayasu, Hiromasa; Pallansch, Mark A; Oberste, Mark S; Moulton, Lawrence H; Halsey, Neal A.
Afiliação
  • Chandir S; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Ahamed KU; Shimantik, Dhaka, Bangladesh.
  • Baqui AH; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Sutter RW; Polio Operations and Research Department, World Health Organization, Geneva, Switzerland.
  • Okayasu H; Polio Operations and Research Department, World Health Organization, Geneva, Switzerland.
  • Pallansch MA; Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Oberste MS; Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Moulton LH; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Halsey NA; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
J Infect Dis ; 210 Suppl 1: S390-7, 2014 Nov 01.
Article em En | MEDLINE | ID: mdl-25316860
ABSTRACT

BACKGROUND:

Polio eradication efforts have been hampered by low responses to trivalent oral poliovirus vaccine (tOPV) in some developing countries. Since stomach acidity may neutralize vaccine viruses, we assessed whether administration of a buffer solution could improve the immunogenicity of tOPV.

METHODS:

Healthy infants 4-6 weeks old in Sylhet, Bangladesh, were randomized to receive tOPV with or without a sodium bicarbonate and sodium citrate buffer at age 6, 10, and 14 weeks. Levels of serum neutralizing antibodies for poliovirus types 1, 2, and 3 were measured before and after vaccination, at 6 and 18 weeks of age, respectively.

FINDINGS:

Serologic response rates following 3 doses of tOPV for buffer recipients and control infants were 95% and 88% (P=.065), respectively, for type 1 poliovirus; 95% and 97% (P=.543), respectively, for type 2 poliovirus; and 90% and 89% (P=.79), respectively, for type 3 poliovirus.

CONCLUSIONS:

Administration of a buffer solution prior to vaccination was not associated with statistically significant increases in the immune response to tOPV; however, a marginal 7% increase (P=.065) in serologic response to poliovirus type 1 was observed. CLINICAL TRIALS REGISTRATION NCT01579825.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Poliomielite / Soluções Tampão / Vacina Antipólio Oral / Excipientes Limite: Female / Humans / Infant / Male País/Região como assunto: Asia Idioma: En Ano de publicação: 2014

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Poliomielite / Soluções Tampão / Vacina Antipólio Oral / Excipientes Limite: Female / Humans / Infant / Male País/Região como assunto: Asia Idioma: En Ano de publicação: 2014